The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials by Miller, RE et al.
The Use of Next Generation Sequencing (NGS) to Guide Patient Selection for Phase 1 
Clinical Trials.  
RE Miller1, N Brown1,2, A Speirs1,2, HM Shaw1, S Adeleke1,2, P Gougis1, P Bennett3, T Meyer1,2, C 
Swanton2,4, MD Forster1,2, and RS Kristeleit1,2 
1UCLH/NIHR Clinical Research Facility, University College London Hospital 
2 UCL Cancer Institute, University College London 
3UCL-Advanced Diagnostics Molecular Profiling Laboratory, Sarah Cannon-UCL Laboratories 
4The Francis Crick Institute, London  
Background: Therapeutically targeting actionable mutations in cancer may increase 
response rates in Phase I clinical trials. We undertook a pilot study to assess the feasibility 
and therapeutic benefit of incorporating NGS screening into the patient pathway for phase 1 
cancer trials.  
Methods: NGS tumour profiling was performed using a 22 gene amplicon-based panel (Life 
Technologies Colon & Lung V2) on 117 consecutive patients (pts) referred for Phase I trials. 
BRCA1/2 analysis was performed in pts with epithelial ovarian cancer. 
Results: 117 pts (67% female) with a median age of 59 (range 22-78) years were included. 
Common tumour types were ovarian (n=20), colorectal (n=16), breast (n=13), endometrial 
(n=12) and lung (n=8) cancer. NGS was successfully performed in 108 (92%) pts with a 
median time to results of 12 days (range 6-39). 82% of pts (89/108) had a detected variant in 
≥ 1 gene with an average of 3 variants (range 0-26) in 2 genes (0-10) per case. Common 
mutations included TP53 (69%), KRAS (14%), PIK3CA (11%) and SMAD4 (9%). BRCA1/2 
mutations were present in 11 (55%) ovarian cancer pts. Overall, 49 (45%) pts had ≥ 1 
actionable mutation. Detected variants were reviewed in a local genomics review board to 
assess actionability prior to considering therapy. 53 pts were commenced on a Phase I trial; 
18 (34%) were genotype directed. Median duration on trial was 73 days for both patients pts 
on genotype (7-260 days) or non-genotype (20-582) directed trials (range 7-260 days) and 
non-genotype directed trials (20-582) with 50% and 24% of allocated patients continuing on 
study respectively. Of pts evaluable for response (n=47), partial response (PR), stable 
disease (SD) and progressive disease (PD) were observed in 50%, 29% and 21% of pts on 
genotype directed trials and 20%, 37% and 43% of pts on non-genotype directed 
respectively. Excluding pts on BRCA1/2 directed trials, PR, SD and PD were observed in 
33%, 33% and 33% of pts respectively in genotype-directed studies. 
Conclusions: NGS is feasible in real time and may affect clinical outcome in the phase 1 
setting. Almost half of pts had a potentially actionable mutation. Initial response rates for 
patients treated on genotype-driven trials are encouraging. Benefit is likely to be augmented 
using a broader NGS panel which is planned for future assessment.  
 
